About 24,003 results

ALLMedicine™ Fatty Liver Center

Research & Reviews  8,681 results

The effect of endurance training on non-alcoholic fatty liver disease in mice.
Physiological Reports; Melo L, Bilici M et. al.

Aug 4th, 2021 - Chronic endurance exercise is a therapeutic strategy in the treatment of non-alcoholic fatty liver disease (NAFLD). Metabolic, cardiorespiratory, and endocrine pathways targeted by chronic endurance exercise have been identified; however, the spec...

Hormonal regulation of glycine decarboxylase and its relationship to oxidative stress.
Physiological Reports; Jog R, Chen G et. al.

Aug 4th, 2021 - In both humans and rodent models, circulating glycine levels are significantly reduced in obesity, glucose intolerance, type II diabetes, and non-alcoholic fatty liver disease. The glycine cleavage system and its rate-limiting enzyme, glycine deca...

Predictive value of cytokeratin-18 fragment levels for diagnosing steatohepatitis in pa...
European Journal of Gastroenterology & Hepatology; Tada T, Saibara T et. al.

Aug 3rd, 2021 - Several noninvasive markers have been developed to predict nonalcoholic steatohepatitis (NASH). We investigated the predictive value of the cytokeratin-18 fragment (CK18-F) level and FIB-4 index for diagnosing NASH in patients with nonalcoholic fa...

Risk stratification using sarcopenia status among subjects with metabolic dysfunction-a...
Journal of Cachexia, Sarcopenia and Muscle; Chun HS, Kim MN et. al.

Aug 3rd, 2021 - Sarcopenia is a significant indicator of the severity of non-alcoholic fatty liver disease. We investigated whether sarcopenia could identify subgroups with different risk of liver fibrosis and atherosclerotic cardiovascular disease (ASCVD) among ...

An adverse outcome pathway based in vitro characterization of novel flame retardants-in...
Environmental Pollution (Barking, Essex : 1987); Negi CK, Bajard L et. al.

Aug 3rd, 2021 - A wide range of novel replacement flame retardants (nFRs) is consistently detected in increasing concentrations in the environment and human matrices. Evidence suggests that nFRs exposure may be associated with disruption of the endocrine system, ...

see more →

Guidelines  14 results

Clinics and Research in Hepatology and Gastroenterology; Boursier J, Guillaume M et. al.

Aug 1st, 2021 - NAFLD is a frequent disease that affects 25% of the worldwide population. There is no specific diagnostic test for NAFLD, and the diagnosis mainly relies on the elimination of the other causes of chronic liver diseases with liver biopsy kept for u...

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease.
Clinical and Molecular Hepatology; Kang SH, Lee HW et. al.

Jun 23rd, 2021 - KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease.|2021|Kang SH,Lee HW,Yoo JJ,Cho Y,Kim SU,|

AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achie...
Gastroenterology Younossi ZM, Corey KE et. al.

Dec 12th, 2020 - Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, with global public health impact affecting more than 25% of the global population. NAFLD is associated with significant morbidity and mortality from cirrhosis, h...

Latin American Association for the study of the liver (ALEH) practice guidance for the ...
Annals of Hepatology; Arab JP, Dirchwolf M et. al.

Oct 9th, 2020 - Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20-30% of the general population. Furthermore, its prevalence is predicted to increase ex...

ACG Clinical Guideline: Alcoholic Liver Disease.
The American Journal of Gastroenterology; Singal AK, Bataller R et. al.

Jan 18th, 2018 - Alcoholic liver disease (ALD) comprises a clinical-histologic spectrum including fatty liver, alcoholic hepatitis (AH), and cirrhosis with its complications. Most patients are diagnosed at advanced stages and data on the prevalence and profile of ...

see more →

Drugs  14 results see all →

Clinicaltrials.gov  255 results

Personalized Nutrition for Pre-Diabetes

Apr 22nd, 2020 - Blood glucose levels are rapidly increasing in the population, as evident by the sharp incline in the prevalence of prediabetes and impaired glucose tolerance estimated to affect, in the U.S. alone, 37% of the adult population. Chronic hyperglycae...

A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver

Mar 31st, 2020 - This study is looking at the effect of semaglutide on subjects with nonalcoholic fatty liver disease.This study is comparing the change in early stages of scar tissue in the liver and fat deposition in the liver in people taking semaglutide and pl...

Tissue-specific Insulin Resistance in Obstructive Sleep Apnea: Role of Hypoxia

Mar 24th, 2020 - Obstructive sleep apnea (OSA) is a common condition associated with significant adverse health outcomes. An estimated 25% of men and 10% of women will have OSA during their lifetime. OSA is associated with an increased prevalence of insulin resist...

De Novo Lipogenesis in Severity of NAFLD

Mar 24th, 2020 - The development of nonalcoholic fatty liver disease (NAFLD) progresses from a state of elevated intrahepatic triglycerides (IHTG) to liver inflammation, and ultimately, hepatic apoptosis and fibrosis. NAFLD is the most prevalent liver disease in t...

Study of ISIS 703802 in Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

Mar 13th, 2020 - This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 703802 and to assess the efficacy of different doses and dosing regimens of ISIS 703802 on glucose and ...

see more →

News  625 results

With Tirzepatide, a 'Great Future' for Patients With T2D

Jul 15th, 2021 - This transcript has been edited for clarity. I'm here to talk about tirzepatide, a dual GIP/GLP-1 receptor agonists that's under investigation for the management of type 2 diabetes, obesity, and fatty liver disease. We're all very used to GLP-1 re...

Resmetirom Shows Promise for Fatty Liver in Early Analysis

Jul 1st, 2021 - The experimental oral drug resmetirom appears to reverse biomarkers for nonalcoholic steatohepatitis (NASH), researchers report. Patients taking the drug in an open-label arm of the phase 3 Maestro-NAFLD-1 trial showed a rapid reduction in hepatic...

Calories May Outweigh Nutrients in Diets for Fatty Liver

Jun 25th, 2021 - Intermittent calorie restriction offers only modest advantages over a low-carbohydrate, high-fat diet (LCHF) for treating nonalcoholic fatty liver disease (NAFLD), researchers say. The intermittent diet offers more benefit for liver stiffness and ...

Waist Circumference Predicts Risk of Fatty Liver in Type 1 Diabetes

Jun 14th, 2021 - Dr Erika B. Parente It follows that, as the prevalence of obesity among people with type 1 diabetes mellitus (T1DM) increases, so would the incidence of nonalcoholic fatty liver (NAFL), as it does in type 2 diabetes. However, researchers in Finlan...

UK Faces a Liver Disease 'Ticking Time Bomb' Fuelled by Rising Rates of Obesity

Jun 11th, 2021 - The British Liver Trust is calling for greater awareness of a silent yet serious form of non-alcoholic fatty liver disease (NAFLD), non-alcohol-related steatohepatitis (NASH), as one million adults were reported to have been admitted to hospitals ...

see more →

Patient Education  12 results see all →